Back to top
more

Dare Bioscience (DARE)

(Delayed Data from NSDQ)

$0.30 USD

0.30
974,742

+0.01 (4.39%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $0.30 0.00 (1.66%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for DARE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Dare Bioscience, Inc. [DARE]

Reports for Purchase

Showing records 1 - 20 ( 211 total )

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

04/01/2024

Daily Note

Pages: 5

Termination of Coverage

Provider: Dawson James Securities, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

02/23/2024

Company Report

Pages: 5

Neutral Rated: Dare to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

02/01/2024

Daily Note

Pages: 3

Progress in Sildenafil Cream Phase 3 Pivotal Study Plan; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

01/30/2024

Company Report

Pages: 5

Lowering to Neutral: Red Flags Abound, Is a reverse Stock Split Next?

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

12/26/2023

Company Report

Pages: 5

BUY: Sells of Future XACIATO Royalties (and Warrants) for $12M, $5M at Closing with an Additional $7M Possible

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/10/2023

Company Report

Pages: 5

3Q Update as Xaciato Finally Launches; Reiterate Buy; PT Down to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/07/2023

Company Report

Pages: 5

BUY: FSAD is Real and Sildenafil Cream Shows Activity - Additional P2B Data from the RESPOND Study

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

10/25/2023

Daily Note

Pages: 4

Biotechnology -Healthcare Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/20/2023

Company Report

Pages: 5

BUY: Daré Bioscience announces first shipment of XACIATO

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

09/19/2023

Industry Report

Pages: 8

Our Top Nuggets from HC Wainwright Global Investment Conference

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/30/2023

Company Report

Pages: 5

BUY: Raises $7M for 10M shares ( 10M Warrants) at $0.70

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/11/2023

Company Report

Pages: 5

Daré Has Two Phase 3 Studies in the Works as We Wait for Xaciato Launch; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/11/2023

Daily Note

Pages: 4

TRANSFERRING COVERAGE

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

07/31/2023

Company Report

Pages: 4

NICHD Grant to Aid Preclinical Studies in Idiopathic Preterm Birth

Provider: Roth Capital Partners, Inc.

Analyst: RAJA K

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

07/13/2023

Daily Note

Pages: 5

Another Look at Sildenafil Cream Tells Us It Shouldn''t Be Overlooked

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

07/13/2023

Company Report

Pages: 5

BUY: CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

07/05/2023

Company Report

Pages: 5

BUY: Dare Provides an Update on the Launch of XACIATO

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

06/20/2023

Company Report

Pages: 5

BUY: Steady Progress as We Move in the Second Half

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

06/06/2023

Daily Note

Pages: 4

Sildenafil Cream Phase 2 Sets the Path Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Dare Bioscience, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/05/2023

Company Report

Pages: 5

Phase 2b Topline Data Meaningful, Full Data Evaluation for Next Steps

Provider: Roth Capital Partners, Inc.

Analyst: RAJA K

Price: 5.00

Research Provided by a Third Party